Learning to live better with lupus: the Health Improvement and Prevention Program (HIPP) in systemic lupus erythematosus

Submission date	Recruitment status	Prospectively registered
16/06/2008	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
16/06/2008	Completed	☐ Results
Last Edited	Condition category	Individual participant data
19/02/2019	Musculoskeletal Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

http://www.canios.ca/About_canios_studies_HIPP.aspx?AspxAutoDetectCookieSupport=1

Contact information

Type(s)

Scientific

Contact name

Dr Paul R. Fortin

Contact details

UHN - TWH Research Institute
Toronto Western Hospital, MP10-304
399 Bathurst Street
Toronto, Ontario
Canada
M5T 2S8
+1 416 603 6265
pfortin@uhnresearch.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00188357

Secondary identifying numbers

MCT-82939

Study information

Scientific Title

The Health Improvement and Prevention Program (HIPP) in systemic lupus erythematosus: a randomised, cross-over, open-label efficacy study

Acronym

HIPP

Study objectives

- 1. The Health Improvement and Prevention Program (HIPP) will improve the physical component (PCS) and mental component (MCS) summary scores of the 36-item short form (SF-36) health status survey by an average of 4 points
- 2. HIPP will reduce the Framingham 8-year projected risk of cardiovascular disease (CVD) in persons with systemic lupus erythematosus (SLE) by 20%
- 3. HIPP will improve the flow mediated dilatation (FMD) of brachial arteries significantly

Ethics approval required

Old ethics approval format

Ethics approval(s)

- 1. Research Ethics Board of the University Health Network, Toronto approved on the 13th January 2004 (ref: 03-0605-A)
- 2. Research Ethics Board of McGill University approved on the 1st December 2006 (ref: 03-034)
- 3. Research Ethics Board of the University of Western Ontario approved on the 31st January 2008 (ref: 13732)

Study design

Randomised, cross-over, open-label efficacy study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Patient information material can be found at http://www.canios.ca/About_canios_studies_HIPP. aspx?AspxAutoDetectCookieSupport=1

Health condition(s) or problem(s) studied

Systemic lupus erythematosus

Interventions

Experimental interventions:

- 1. Non-drug coronary artery risk reduction in the setting of lupus measured at three months for one year followed by every six months for one year
- 2. Non-drug osteoporosis risk reduction in the setting of lupus measured at three months for one year followed by every six months for one year
- 3. Non-drug exercise in the setting of lupus measured at three months for one year followed by every six months for one year
- 4. Non-drug mindfulness based stress reduction in the setting of lupus measured at three months for one year followed by every six months for one year

Control intervention:

Usual care for 12 months.

Added 26/02/2009:

Secondary sponsor details:
Toronto Western Hospital (Canada)
c/o Dr. Paul Fortin
University Health Network
399 Bathurst Street
MP-10-304
Toronto, Ontario, M5T-2S8
Canada

Tel: +1 416 603 5800 ext. 6267

Fax: +1 416 603 6288

Email: pfortin@uhnresearch.ca

Contact for public queries: Dr Ellie Aghdassi, Ph.D. University Health Network Toronto Western Hospital 399 Bathurst Street MP-10-301 Toronto, Ontario, M5T-2S8 Canada

Tel: +1 416 603 5800 ext. 2822

Fax: +1 416 603 6288

Email: ellie.aghdassi@uhn.on.ca

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

36-item short form health survey physical and mental component summary scale (SF-36 PCS and MCS) scores, coronary disease risk reduction profiles and flow-mediated dilatation of the brachial artery yearly for two years.

Secondary outcome measures

- 1. Bone health improvement: yearly while on prednisone; every two years for all others
- 2. Adherence to treatment: every three months for one year and every six months for one year

Overall study start date

01/08/2003

Completion date

01/12/2010

Eligibility

Key inclusion criteria

- 1. Systemic lupus erythematosus according to American College of Rheumatology (ACR) criteria
- 2. 18 years or older
- 3. Female
- 4. Able to read and English or French

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

310 patients to enroll (to achieve 260 completers)

Key exclusion criteria

- 1. History of angina
- 2. Myocardial infarct
- 3. Cerebral vascular accident
- 4. Trans-ischaemic attack
- 5. Peripheral vascular disease
- 6. Osteoporosis with fracture confirmed by radiology
- 7. Pregnant or planning within two years
- 8. Cancer (if cancer-free for five years then eligible)

Date of first enrolment

01/08/2003

Date of final enrolment

01/12/2010

Locations

Countries of recruitment

Canada

Study participating centre
UHN - TWH Research Institute
Toronto, Ontario
Canada
M5T 2S8

Sponsor information

Organisation

University Health Network (Canada)

Sponsor details

200 Elizabeth Street Toronto, Ontario Canada M5G 2C4

Sponsor type

University/education

Website

http://www.uhn.ca/index.htm

ROR

https://ror.org/042xt5161

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-82939)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration